Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide + R-CHOP versus placebo + placebo + R-CHOP in untreated high-risk DLBCL
2020-002990-84Phase 3Active
- Sponsor
- MorphoSys AG
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafasitamab, lenalidomide, rituximab, cyclophosphamide, doxorubicin and 2 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by MorphoSys AG. Primary endpoint: Progression-free survival. Started Dec 2020; status: active.
02
Drugs
tafasitamablenalidomiderituximabcyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2020-002990-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002990-84.